MX2022011051A - Inhibidores peptidicos de la proteina 1 que interactua con quinasa c (pick1) conjugados con lipido. - Google Patents

Inhibidores peptidicos de la proteina 1 que interactua con quinasa c (pick1) conjugados con lipido.

Info

Publication number
MX2022011051A
MX2022011051A MX2022011051A MX2022011051A MX2022011051A MX 2022011051 A MX2022011051 A MX 2022011051A MX 2022011051 A MX2022011051 A MX 2022011051A MX 2022011051 A MX2022011051 A MX 2022011051A MX 2022011051 A MX2022011051 A MX 2022011051A
Authority
MX
Mexico
Prior art keywords
pick1
peptide
lipid
peptide inhibitors
lipid conjugated
Prior art date
Application number
MX2022011051A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth L Madsen
Ulrik Gether
Nikolaj Riis Christensen
Original Assignee
Univ Copenhagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Copenhagen filed Critical Univ Copenhagen
Publication of MX2022011051A publication Critical patent/MX2022011051A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
MX2022011051A 2020-03-06 2021-03-05 Inhibidores peptidicos de la proteina 1 que interactua con quinasa c (pick1) conjugados con lipido. MX2022011051A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20161493 2020-03-06
PCT/EP2021/055678 WO2021176094A1 (en) 2020-03-06 2021-03-05 Lipid conjugated peptide inhibitors of pick1

Publications (1)

Publication Number Publication Date
MX2022011051A true MX2022011051A (es) 2022-12-15

Family

ID=69780027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011051A MX2022011051A (es) 2020-03-06 2021-03-05 Inhibidores peptidicos de la proteina 1 que interactua con quinasa c (pick1) conjugados con lipido.

Country Status (10)

Country Link
US (1) US20230346948A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114524A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023506598A (cg-RX-API-DMAC7.html)
KR (1) KR20220150313A (cg-RX-API-DMAC7.html)
CN (1) CN115362001A (cg-RX-API-DMAC7.html)
AU (1) AU2021232645B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022017673A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168324A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011051A (cg-RX-API-DMAC7.html)
WO (1) WO2021176094A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2111413A2 (en) * 2007-02-16 2009-10-28 Genetech, Inc. Htra1-pdz and htra3-pdz modulators
KR102046830B1 (ko) * 2011-05-13 2019-11-20 코벤하븐스 유니버시테트 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 psd-95의 고-친화성, 이량체 저해제
PL3074032T3 (pl) * 2013-12-01 2019-06-28 University Of Copenhagen Pochodne kwasów tłuszczowych dimerycznych inhibitorów psd-95
WO2020083905A1 (en) 2018-10-22 2020-04-30 University Of Copenhagen Inhibitors of pick1 and uses thereof

Also Published As

Publication number Publication date
BR112022017673A2 (pt) 2022-11-08
AU2021232645B2 (en) 2026-07-09
WO2021176094A1 (en) 2021-09-10
US20230346948A1 (en) 2023-11-02
AU2021232645A1 (en) 2022-09-15
CA3168324A1 (en) 2021-09-10
KR20220150313A (ko) 2022-11-10
CN115362001A (zh) 2022-11-18
EP4114524A1 (en) 2023-01-11
JP2023506598A (ja) 2023-02-16

Similar Documents

Publication Publication Date Title
PH12020551205A1 (en) Fap inhibitors
DOP2015000043A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes
PH12018502038A1 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CO6480950A2 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
Rivera-Valentin et al. Bone sarcomas in pediatrics: progress in our understanding of tumor biology and implications for therapy
NZ704269A (en) Rspo3 binding agents and uses thereof
ECSP12012020A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes
CY1110322T1 (el) Αναστολεις της her3 δραστικοτητας
EA201490622A1 (ru) Агенты, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение
MX2009009146A (es) Metodos y objetivos para identificar compuestos para regular la infeccion por rinovirus.
BR112012004546A8 (pt) Terapêutica por proteínas ligantes dll4-ligantes
EP2949344A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
UA95304C2 (ru) Применение антагониста dll4 для предотвращения или снижения потери кровеносных сосудов
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
GEP20135826B (en) Novel antibodies used to treat cancer
WO2009068659A3 (en) Novel disease treatment by predicting drug association
CN110461836A (zh) 一种选择性抑制激酶化合物及其用途
WO2020198662A8 (en) Clec9a-based chimeric protein complexes
MX2026000307A (es) Ligando de proteina para la activacion de fibroblastos y su uso
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2024005948A (es) Composiciones de complejos de proteinas y metodos de uso de estos.
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
EP1841420A4 (en) TREATMENT OF REMEDIENT-RESISTANT PROLIFERATIVE DISEASES
BR112022017673A2 (pt) Inibidor de interação de proteína com c cinase ? 1, micela, e, composição farmacêutica